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Introduction {#sec001}
============

Infections due to *Enterobacteriaceae* are an important cause of morbidity and mortality worldwide. Use of antimicrobial agents is the main stay of treatment of such infections. However, resistance to these agents has become a serious health concern worldwide \[[@pone.0152638.ref001]\]. Carbapenems, e.g. imipenem and meropenem, are the last choice to treat multidrug- resistant (MDR) Gram-negative bacterial infections \[[@pone.0152638.ref002]\]. Infections due to carbapenem-resistant *Enterobacteriaceae* (CRE) are increasingly reported throughout the world and the Centers for Disease Control and Prevention (CDC), USA considers them as an urgent threat to human health \[[@pone.0152638.ref003]\]. Carbapenem resistance in *Enterobacteriaceae* can be mediated by production of carbapenemases which are encoded by different genes \[[@pone.0152638.ref002]\]. Carbapenemases in *Enterobacteriaceae* can be divided into Ambler class A β- lactamases (e.g. KPC), class B metallo-β-lactamases (MBLs) (e.g. VIMs, IMPs, NDMs) and class D oxacillinases (e.g. OXA-48 like enzymes) \[[@pone.0152638.ref002]\]. New Delhi metallo-β-lactamase-1 (NDM-1), a relatively newly described MBL, can hydrolyze all β-lactams including carbapenems except monobactam. It was first identified in *Klebsiella pneumoniae* and *Escherichia coli* isolated from a Swedish patient who was hospitalized in India in 2008 \[[@pone.0152638.ref004]\]. Since then, it has spread all over the world. To-date, NDM-1-producing-bacteria have been found in over 40 countries creating a significant public health threat \[[@pone.0152638.ref001], [@pone.0152638.ref005], [@pone.0152638.ref006]\]. NDM-1 producing bacteria are particularly important because the gene encoding this enzyme is found on transferable plasmid (of varying size) so that resistance can be easily transferred from one bacterium to another. These bacteria are usually multi-drug resistant making treatment difficult. NDM-1-positive isolates are also colonizers, causing no disease and therefore screening for them can be difficult. Importantly, NDM-1 enzyme is also present in *E*. *coli*, the most common cause of urinary tract infection in the community and hospital \[[@pone.0152638.ref007], [@pone.0152638.ref008]\].

Kuwait is a Middle-Eastern country of 3.5 million people, the majority of whom are expatriates from numerous countries. This population mix provides ample opportunities for introduction and spread of resistant bacteria. In Kuwait, NDM-1 producing *K*. *pneumoniae* was first identified in two hospitalized patients \[[@pone.0152638.ref009]\]. A subsequent study in a major teaching hospital found that *K*. *pneumoniae* was the main species that expresses NDM-1 \[[@pone.0152638.ref010]\]. However, the magnitude of carbapenem resistance due to NDM-1 in *Enterobacteriaceae* in Kuwait is unknown. We therefore, conducted a surveillance study to detect carbapenem-resistant *Enterobacteriaceae* carrying NDM-1 gene in four major hospitals in Kuwait over a one---year period.

Materials and Methods {#sec002}
=====================

A surveillance study was conducted in four major teaching/public hospitals in Kuwait (Amiri, Farwaniya, Ibn Sina, and Mubarak Al Kabeer hospitals) responsible for healthcare delivery to a catchment area of 2.5 million people. Consecutive clinically significant (suspected of causing infection or carriage) isolates of the family *Enterobacteriaceae* were collected from a total of 764 patients during one year, January to December 2014. These were non-duplicate single isolate per patient. The contribution from each hospital was as follows: Amiri hospital, 208; Farwaniya hospital, 123; Ibn Sina hospital, 210; and Mubarak Al Kabeer hospital, 223. The isolates were from different sources e.g. urine, wound and tissue, blood, respiratory secretion, abscess, central venous pressure line tip, peritoneal dialysis fluid, cerebrospinal fluid, pericardial fluid and screening rectal and throat swabs.

Bacterial isolates {#sec003}
------------------

A total of 61 non-susceptible isolates to at least one of the carbapenems, with a minimum inhibitory concentration (MIC) of \>1mg/L for imipenem or meropenem, or \>0.5mg/L for ertapenem, according to the Clinical and Laboratory Standards Institute (CLSI) \[[@pone.0152638.ref011]\] were included in the study. They were stored at -70°C in 1% protease/peptone broth containing 7% glycerol for further evaluation. Species identification was performed with VITEK II automated system (bioMérieux, Marcy l'Etoile, France).

Antimicrobial susceptibility testing and phenotypic assays {#sec004}
----------------------------------------------------------

Antibiotic susceptibility testing was performed using E test (bioMérieux). The tested antibiotics were: amikacin and gentamicin (aminoglycosides); ampicillin, amoxicillin-clavulanic acid and piperacillin-tazobactam (β-lactams); aztreonam (monobactam); cephalothin, cefepime, cefotaxime, cefoxitin, ceftazidime, and cefuroxime (cephalosporins); ciprofloxacin (quinolone); colistin (polymyxin); ertapenem, imipenem and meropenem (carbapenems) and tigecycline (glycylcycline). Susceptibility testing was interpreted according to the Clinical Laboratory Standards Institute (CLSI) recommendations \[[@pone.0152638.ref011]\], except for tigecycline and colistin. For tigecycline, we used the breakpoints recommended by the Food and Drug Administration, USA (i.e. susceptible if MIC was ≤ 2mg/L and resistant if MIC was ≥ 8mg/L). For colistin, breakpoints recommended for *Acinetobacter* spp. was used (i.e. MIC of ≤ 2mg/L for susceptibility and MIC of ≥ 4mg/L for resistance) \[[@pone.0152638.ref011]\]. *E*. *coli* ATCC 25922 and *E*. *coli* ATCC 35218 strains were used as controls. Initial screening for the presence of carbapenemase was done by the modified Hodge test (MHT) \[[@pone.0152638.ref011]\] and E test. *K*. *pneumoniae* ATCC BAA-1705 and *K*. *pneumoniae* ATCC BAA-1706 were used as positive and negative controls, respectively.

PCR amplifications and sequencing {#sec005}
---------------------------------

PCR assays were used to amplify the extended-spectrum β-lactamases (ESBLs) genes- *bla*~CTX-M~, *bla*~SHV~ and *bla*~TEM~, \[[@pone.0152638.ref012]\] and the carbapenemase genes- *bla*~OXA-48~, *bla*~VIM~, *bla*~NDM~, *bla*~IMP~, *bla*~GIM~ and *bla*~KPC~ \[[@pone.0152638.ref013]\]. Sequencing of the amplicons was performed using a GenAmp PCR system 9700 by cycle sequencing with BigDye terminator (AB Applied Biosystem, Carlsbad, California, USA).

Molecular finger printing {#sec006}
-------------------------

Clonal relatedness of the *K*. *pneumoniae* and *E*. *coli* isolates was investigated by semi-automated repetitive sequence-based polymerase chain reaction (rep-PCR) using the DiversiLab^®^ strain typing platform (bioMérieux). It was performed in duplicate with the DiversiLab^®^ *Klebsiella* spp. kit and *Escherichia* spp. kit, according to manufacturer's instructions. The resulting electropherograms were analyzed with DiversiLab software version 3.4 (bioMérieux). Samples were compared by automatically generated dendrograms calculated using the unweighted pair- group method with arithmetic mean (UPGMA) algorithm. In DiversiLab^®^, the cut-off limits for identity, similarity and dissimilarity for both *E*. *coli* and *K*. *pneumoniae* are ≥ 98%, ≥ 95% and \< 95% respectively, \[[@pone.0152638.ref014], [@pone.0152638.ref015]\].

Ethics statement {#sec007}
----------------

Collection of the strains was conducted according to the Declaration of Helsinki and with particular institutional ethical and professional standards. A written informed consent was not obtained from patients or parents of children because the bacterial isolates studied were collected from the routine work of clinical microbiology laboratory for patient care and no additional clinical specimens were collected for the purpose of the study. It is a standard practice not to get written informed consent for use of bacterial isolates unlinked to patient identity from the routine clinical laboratory. Therefore, the waiver for informed consent was granted and the study was approved by the Medical Ethics Committee of Ministry of Health, Kuwait approved the study (permit number 288/MTT).

Results {#sec008}
=======

Bacterial isolates {#sec009}
------------------

Sixty one (8%) of 764 *Enterobacteriaceae* isolates collected were carbapenem- resistant *Enterobacteriaceae* (CRE) made up of *K*. *pneumoniae* (n = 25), *E*. *coli* (n = 22), *Morganella morganii* (n = 6), *Enterobacter cloacae* (n = 5), *Enterobacter aerogenes* (n = 2), and *Providencia stuartii* (n = 1). Of these 61 CRE, 21 (34.4%) were positive for *bla*~NDM-1~ and belonged to different bacterial species: *K*. *pneumoniae* (n = 14; 66.6%), *E*. *coli* (n = 4; 19%), *E*. *cloacae* (n = 1; 4.7%), *M*. *morganii* (n = 1; 4.7%) and *P*. *stuartii* (n = 1; 4.7%). The clinical features and characteristics of these 21 patients are shown in [Table 1](#pone.0152638.t001){ref-type="table"}. The age of the patients ranged from 5 months to 83 years (mean = 53.3 years). Male---to---female ratio was 10:11 (0.9). The majority were Kuwaitis (n = 14; 66.6%) followed by Indians (n = 4; 19%) and one each from Egypt, Iran and Syria (4.8%). They were all residents of Kuwait. All the patients with NDM-1 positive isolates were infected except two patients who were colonized in the rectum, and throat (patient numbers 9 and 15, respectively). Before development of CRE infection, patients received prior antimicrobial therapies numbering from one to 7 antimicrobial agents. Fifteen (71.4%) patients were discharged alive from the hospital, while all 6 (28.6%) patients with sepsis and septic shock died.

10.1371/journal.pone.0152638.t001

###### Clinical features and patient characteristics associated with carbapenem-resistant *Enterobacteriaceae* isolates producing NDM-1.

![](pone.0152638.t001){#pone.0152638.t001g}

  Patient   Age/ gender     Nationality   Underlying disease                                                            Organism                 Antibiotic therapy                  Outcome
  --------- --------------- ------------- ----------------------------------------------------------------------------- ------------------------ ----------------------------------- ------------------
  1         83y/male        Kuwaiti       Chest infection, Right hip replacement                                        *E*. *coli*              TZP, CLAR                           Survived
  2         52y/male        Indian        Bladder cancer, DM, BP                                                        *Morganella morganii*    AMC, CIP, NIT, CST                  Survived
  3         82y/female      Egyptian      CVA, BP, epilepsy, aspiration pneumonia, infected bed sore                    *K*. *pneumoniae*        FEP, MTZ, MEM, TGC, CST             Died from sepsis
  4         53y/male        Indian        Bilateral urolithiasis                                                        *E*. *coli*              AMK, CRO                            Survived
  5         80y/female      Kuwaiti       CVA, DM, CKD on dialysis, DVT, PVD                                            *K*. *pneumoniae*        CIP, AMK,                           Survived
  6         78y/female      Kuwaiti       DM, IHD, obstructive uropathy, CKD                                            *K*. *pneumoniae*        MEM, AMB, CIP, VAN                  Survived
  7         66y/male        Kuwaiti       DM, BP, CVA aspiration pneumonia, CVA                                         *Providencia stuartii*   MEM, CIP, TZP, CRO                  Died from sepsis
  8         1y/female       Indian        Atypical familial uremic syndrome                                             *K*. *pneumoniae*        AMC, GEN                            Survived
  9         5month/female   Kuwaiti       Left sided hip dislocation, bronchial asthma, pneumonia                       *E*. *coli*              CTX                                 Survived
  10        56y/male        Syrian        Bilateral obstructive uropathy, BP, kidney stones                             *Enterobacter cloacae*   CRO                                 Survived
  11        67y/female      Kuwaiti       DM, BP, old CVA, IHD, bronchial asthma, thyroidectomy                         *K*. *pneumoniae*        TZP, CLAR, MEM, CAZ, CST            Died from sepsis
  12        68y/female      Kuwaiti       BP, DM, atrial fibrillation, CVA                                              *K*. *pneumoniae*        TZP, CAZ, CRO, MEM, FEP, TEC FLC    Survived
  13        60y/female      Kuwaiti       DM, BP, mixed connective tissue disease, pneumonia                            *K*. *pneumoniae*        TZP, MTZ                            Survived
  14        69y/female      Kuwaiti       CML, DM, BP                                                                   *K*. *pneumoniae*        TZP, VAN, AMK, MEM, FLC             Died from sepsis
  15        34y/male        Iranian       Drug overdose, cardiac arrest, hypoxic encephalopathy, aspiration pneumonia   *K*. *pneumoniae*        CRO, MTZ, TZP, IPM, MEM, TGC, CST   Survived
  16        36y/female      Kuwaiti       SLE, lupus nephritis, hereditary elliptocytosis                               *E*. *coli*              FLC                                 Survived
  17        48y/male        Indian        DM, BP, CVA                                                                   *K*. *pneumoniae*        CRO, CLAR, MEM, CST                 Died from sepsis
  18        43y/female      Kuwaiti       Kidney transplant, BP, DM                                                     *K*. *pneumoniae*        CRO, MEM                            Survived
  19        45y/male        Kuwaiti       Kidney transplant, DM, sepsis                                                 *K*. *pneumoniae*        TPZ, MEM                            Died from sepsis
  20        54y/male        Kuwaiti       Kidney transplant, DM, IHD                                                    *K*. *pneumoniae*        TZP, MEM, CAZ                       Survived
  21        43y/male        Kuwaiti       Kidney transplant, DM, polycystic kidney disease                              *K*. *pneumoniae*        MEM, CTX, CIP                       Survived

DM = Diabetes mellitus; BP = hypertension; CVA = cerebrovascular accident; CKD = chronic kidney disease; IHD = ischemic heart disease; DVT = deep venous thrombosis; PVD = peripheral vascular disease; IHD = ischemic heart disease; CML = chronic myeloid leukemia; SLE = systemic lupus erythematosus; TZP = piperacillin-tazobactam; CLAR = clarithromycin; AMC = amoxicillin-clavulanic acid; CIP = ciprofloxacin; NIT = nitrofurantoin; CST = colistin; FEP = cefepime; MTZ = metronidazole; MEM = meropenem; TGC = tigecycline; AMK = amikacin; AMB = amphotericin B; VAN = vancomycin; CRO = ceftriaxone; GEN = gentamicin; CTX = cefotaxime; CAZ = ceftazidime; TEC = teicoplanin; FLC = fluconazole; IPM = imipenem.

As shown in [Table 2](#pone.0152638.t002){ref-type="table"}, the most common infections caused by NDM-1 positive isolates were urinary tract infection (UTI) (n = 10; 47.6%) followed by blood stream infection (BSI) (n = 5; 23.8%), wound/tissue infection (n = 3; 14.3%) and central venous pressure tip infection (n = 1; 4.8%). The remaining 2 patients were colonized as demonstrated by positive rectal and throat screening. All Indian, Syrian, Iranian and Egyptian patients had a recent travel history to their native countries within the previous 1--3 months before admission to the hospital, while only 3 of the Kuwaiti patients had a history of travel to Jordan, India and USA within the previous 1--3 months before hospital admission.

10.1371/journal.pone.0152638.t002

###### Source, travel history and ESBL-encoding gene co-harbored by NDM-1 producing *Enterobacteriaceae* isolates.

![](pone.0152638.t002){#pone.0152638.t002g}

  Patient number (organism)     Specimen source         Associated β-lactamases   History of travel   Co-harbored MBL gene(s)
  ----------------------------- ----------------------- ------------------------- ------------------- -------------------------
  1 (*E*. *coli*)               Urine                   CMY-4, CTX-M-27           None                None
  2 (*M*. *morganii*)           Urine                   None                      India               None
  3 (*K*. *pneumoniae*)         Blood                   CTX-M-15, SHV-1           Egypt               None
  4 (*E*. *coli*))              Urine                   CTX-M-15, CMY-4           India               None
  5 (*K*. *pneumoniae*)         Wound                   CTX-M-15, SHV-1           None                None
  6 (*K*. *pneumoniae*)         Urine                   CTX-M-15, SHV-11          Jordan              None
  7 (*P*. *stuartii*)           Urine                   CTX-M-15                  None                None
  8 (*K*. *pneumoniae*)         Urine                   None                      None                None
  9 (*E*. *coli*)               Screening rectal swab   None                      India               None
  10 (*Enterobacter cloacae*)   Urine                   CMY-4                     Syria               None
  11(*K*. *pneumoniae*)         Urine                   CTX-M-15                  None                OXA-48
  12(*K*. *pneumoniae*)         Blood                   CTX-M15                   None                OXA-48
  13(*K*. *pneumoniae*)         Urine                   CTX-M-15, SHV-1           USA                 KPC, OXA-48
  14(*K*. *pneumoniae*)         Blood                   CTX-M-15, SHV-11          None                KPC, OXA-48
  15(*K*. *pneumoniae*)         Screening throat swab   CTX-M-15, SHV-11          Iran                KPC, OXA-48
  16 (*E*. *coli*)              Urine                   CTX-M-1                   None                None
  17(*K*. *pneumoniae*)         Blood                   CTX-M-1                   India               None
  18(*K*. *pneumoniae*)         Wound                   CMY-4                     None                KPC, OXA-48
  19(*K*. *pneumoniae*)         Blood                   CMY-4                     None                KPC, OXA-48
  20(*K*. *pneumoniae*)         Tissue                  CMY-4                     None                KPC, OXA-48
  21(*K*. *pneumoniae*)         CVP tip                 None                      None                KPC, OXA-48

CVP = Central venous pressure

Susceptibility testing {#sec010}
----------------------

The results of susceptibility testing are shown in [Table 3](#pone.0152638.t003){ref-type="table"}. All NDM-1 positive isolates were highly resistant to ampicillin, amoxicillin-clavulanic acid, cephalothin, cefotaxime, cefoxitin, meropenem and ertapenem. All except one isolates were resistant to cefepime, imipenem and piperacillin-tazobactam. Nineteen (90.5%), 19 (90.5%) and 14 (66.6%) isolates were resistant to aztreonam, ciprofloxacin and amikacin, respectively. Approximately 50% of isolates were resistant to tigecycline. Two *K*. *pneumoniae* isolates were resistant to colistin with an MIC of 4 and 48mg/L respectively, while the *M*. *morganii* and *P*. *stuartii* isolates were resistant to colistin.

10.1371/journal.pone.0152638.t003

###### Antibiotic susceptibility profile of NDM-1-producing *Enterobacteriaceae* with breakpoints (mg/L).

![](pone.0152638.t003){#pone.0152638.t003g}

  Patient number (organism)     AMK (16)   ATM (4)   FEP (8)   FOX (8)   CTX (1)   TZP (4)   CIP (1)   CST (2)   ETP (0.5)   GEN (4)   IPM (1)   MEM (1)   TGC (2)
  ----------------------------- ---------- --------- --------- --------- --------- --------- --------- --------- ----------- --------- --------- --------- ---------
  1 (*E*. *coli*)               256        24        64        256       256       256       32        0.5       8           1024      32        32        1
  2(*M*. *morgannii*)           256        256       256       256       256       256       32        256       4           1024      16        12        4
  3(*K*. *pneumoniae*)          24         24        256       256       256       256       32        .125      32          0.125     32        32        0.75
  4 (*E*. *coli*)               256        256       96        256       256       256       \>32      0.125     \>32        1024      1.5       32        0.25
  5(*K*. *pneumoniae*)          256        256       256       256       256       256       \>32      0.38      \>32        512       32        32        1.5
  6(*K*. *pneumoniae*)          4          64        256       256       256       256       1         0.75      \>32        2         \>32      \>32      1
  7 (*P*. *stuartii*)           1.5        0.25      0.25      256       256       1.5       1.5       256       3           0.125     1         1.5       2
  8(*K*. *pneumoniae*)          16         96        256       256       256       256       0.19      0.38      16          1         32        6         0.75
  9 (*E*. *coli*)               3          0.064     256       256       256       256       \>32      0.25      \>32        24        4         12        0.5
  10 (*Enterobacter cloacae*)   \>256      128       32        256       256       256       12        0.38      \>32        1024      32        32        3
  11(*K*. *pneumoniae*)         16         128       64        256       256       256       32        4         \>32        3         \>32      24        16
  12(*K*. *pneumoniae*)         16         96        256       256       256       256       32        0.75      32          3         \>32      \>32      8
  13(*K*. *pneumoniae*)         256        256       128       256       256       256       16        0.25      \>32        512       \>32      \>32      0.5
  14(*K*. *pneumoniae*)         128        128       256       256       256       256       32        0.38      \>32        64        \>32      \>32      4
  15(*K*. *pneumoniae*)         16         128       256       256       256       256       16        0.25      \>32        64        16        16        0.5
  16 (*E*. *coli*)              128        256       256       256       256       256       32        0.38      \>32        64        \>32      \>32      8
  17(*K*. *pneumoniae*)         32         256       256       256       256       256       32        0.125     \>32        0.125     \>32      \>32      4
  18(*K*. *pneumoniae*)         64         128       256       256       256       256       16        0.38      \>32        64        \>32      \>32      0.5
  19(*K*. *pneumoniae*)         32         128       256       256       256       256       32        48        \>32        128       \>32      \>32      16
  20(*K*. *pneumoniae*)         128        256       256       256       256       256       16        1.5       \>32        512       \>32      \>32      4
  21(*K*. *pneumoniae*)         64         128       256       256       256       256       32        0.38      \>32        128       \>32      \>32      2

The values in parenthesis in the first row are the recommended breakpoints for resistance according to CLSI \[[@pone.0152638.ref011]\]. AMK = amikacin; ATM = aztreonam; FEP = cefepime; FOX = cefoxitin; CTX = cefotaxime; TZP = piperacillin-tazobactam; CIP = ciprofloxacin; CST = colistin; ETP = ertapenem; GEN = gentamicin; IPM = imipenem; MEM = meropenem; TGC = tigecycline.

Detection of ESBLs and carbapenemases {#sec011}
-------------------------------------

None of the *bla*~NDM-1~-positive isolates co-harbored *bla*~VIM~, *bla*~IMIP~ or *bla*~GIM~ carbapenemase- mediating genes. Two of the *bla*~NDM-1~-positive isolates co-harbored *bla*~OXA-48~ carbapenemase and 7 co-harbored both *bla*~OXA-48~ and *bla*~KPC~ genes ([Table 2](#pone.0152638.t002){ref-type="table"}). No other carbapenemase genes were detected in our testing panel for the remaining 40 CRE. Most of these *bla*~NDM-1~-carrying CRE also carried other resistant genes conferring ESBLs i.e. CTX-M and SHV. Among the CTX-M variants, there were 10 (47.6%) isolates carrying *bla*~CTX-M-15~, 1 (4.8%) *bla*~CTX-M-27~ and 2 (9.5%) *bla*~CTX-M-1~ groups. Among the SHV variants, there were 3 (14.3%) SHV-11 and 3 (14.3%) SHV-1 groups.

Clonal relatedness {#sec012}
------------------

Analysis of genetic relatedness of 14 *K*. *pneumoniae* isolates by Diversilab^®^ revealed a similarity of \> 95% for 3 isolates (serial numbers 5, 6, 7; i.e. patients 19, 21 and 20) suggesting a close relationship ([Fig 1](#pone.0152638.g001){ref-type="fig"}). However, 2 of these isolates (serial numbers 5 and 6) were ≥ 98% similar suggesting an identity, thus confirming that the same clone infected two patients within one month period in one hospital. In addition, there was \> 95% similarity between 2 *K*. *pneumoniae* isolates (serial numbers 1 and 2; i.e. patient 17 and 15). Analysis of genetic relatedness among all 4 *E*. *coli* isolates harboring *bla*~NDM-1~ genes revealed an identity of ≥ 98% for 2 isolates (serial numbers 1, 2; patients 1 and 16), suggesting clonality of these 2 isolates causing infection in two adjacent wards ([Fig 2](#pone.0152638.g002){ref-type="fig"}).

![Genetic relatedness analysis of 14 *Klebsiella pneumoniae* isolates with DiversiLab^®^ using repetitive sequence-based polymerase chain reaction (rep-PCR).\
Dendrogram and computer-generated image of rep-PCR banding patterns are shown. Vertical lines indicate similarities of 95% and 98%. MAK W21 = Mubarak Al Kabeer hospital ward 21; MAK ICU = Mubarak Al Kabeer hospital intensive care unit; Amiri W9 = Amiri hospital ward 9; MAK W23 = Mubarak Al Kabeer hospital ward 23; IBS W3 = Ibn Sina hospital ward 3; IBS W2 = Ibn Sina hospital ward 2; IBS ICU = Ibn Sina hospital intensive care unit; MAK Ped ICU = Mubarak Al Kabeer hospital pediatric intensive care unit; MAK W 12 = Mubarak Al Kabeer hospital ward 12; Amiri W7 = Amiri hospital ward 7; MAK W26 = Mubarak Al Kabeer hospital ward 26](pone.0152638.g001){#pone.0152638.g001}

![Genetic relatedness analysis of 4 *E*. *coli* strains by DiversiLab^®^ using repetitive sequence-based polymerase chain reaction (rep-PCR).\
Dendrogram and computer-generated image of rep-PCR banding patterns are shown. Vertical lines indicate similarities of 95% and 98%. MAK W21 = Mubarak Al Kabeer hospital ward; MAK W20 = Mubarak Al Kabeer hospital ward 20; MAK W14 Mubarak Al Kabeer hospital ward 14; MAK W 9 = Mubarak Al Kabeer hospital ward 9](pone.0152638.g002){#pone.0152638.g002}

Discussion {#sec013}
==========

The emergence of NDM-1 producing *Enterobacteriaceae* has become a major public health threat that presents a challenge for treatment of serious infections throughout the world. There are several published reports of NDM-1 carbapenemases worldwide including the Gulf Corporation Council (GCC) countries of Saudi Arabia, Sultanate of Oman, Qatar, United Arab Emirates and Kuwait \[[@pone.0152638.ref016], [@pone.0152638.ref010]\], Yemen \[[@pone.0152638.ref017]\], the West Asian countries of Turkey \[[@pone.0152638.ref018]\], Lebanon \[[@pone.0152638.ref019]\] and Israel \[[@pone.0152638.ref020]\], and North African countries of Egypt \[[@pone.0152638.ref021]\], Tunisia \[[@pone.0152638.ref022]\] and Morocco \[[@pone.0152638.ref023]\]. In our study, 61.9% of the NDM-1 harboring isolates co-expressed ESBLs which is concordant with previous reports \[[@pone.0152638.ref016]--[@pone.0152638.ref019], [@pone.0152638.ref023]\]. The present study reveals the fact that carbapenem resistance among *Enterobacteriaceae* mediated by NDM-1 MBL production is becoming a significant occurrence in several hospitals in Kuwait. NDM-1 was present in 2.7% of all *Enterobacteriaceae* in our study and in about 34.4% of all CRE. This is more than double the 1.2% reported by Kumarasamy and colleagues in 2010 in India, Pakistan and the United Kingdom \[[@pone.0152638.ref024]\] and the 1.1% reported by Tran and colleagues in Vietnam in 2015 \[[@pone.0152638.ref025]\]. The detection of 34.4% of the CRE in our hospitals as NDM-1-producers is alarming. However, 40 of the CRE isolates were negative for all the tested β-lactamases and carbapenemases genes, suggesting the possibility of occurrence of new genes or permeability problems \[[@pone.0152638.ref026], [@pone.0152638.ref019]\].

This report reviews 21 cases of infected or colonized patients caused by NDM-1 positive bacteria in Kuwait. They were recognized over a period of one year. The majority of the isolates were from female patients above the age of 53 years of age. Our data are similar to those reported by Kumarasamy *et al*. from India \[[@pone.0152638.ref024]\], where the majority were female patients but different in the mean ages; 53.3 versus 35years. This is in contrast to the isolates reported from the United Kingdom by Jain and colleagues in 2014, where the majority of their patients were males above 60 years of age \[[@pone.0152638.ref027]\]. About half of our isolates were from UTI (47.6%), a finding similar to the study of Jain *et al*. \[[@pone.0152638.ref027]\]. Other frequent sources were blood stream infection (23.8%) and wound/tissue infections (14.3%). History of travel or healthcare contact in endemic areas was given by more than a quarter of our patients. Some patients also travelled to areas regarded as non-endemic as Middle- Eastern countries (Egypt, Syria, Jordan and Iran) and the USA. None-of these patients had a history of travel to the Balkans, which is suggested to be the second epicenter for NDM-positive bacteria \[[@pone.0152638.ref028]\]. A very high proportion (71.4%) of NDM-1 positive patients had no history of travel to any endemic areas such as India and Pakistan or contact with healthcare facilities which have been reported previously as a source of infection \[[@pone.0152638.ref027], [@pone.0152638.ref029]\]. It appears that all our patients acquired the NDM-1 producing strains while they were in the hospital suggesting nosocomial acquisition. A caveat of this assumption is that the patients were not screened for NDM-1 producing bacteria on the day of hospital admission. Infections due to CRE have been associated with high mortality rates ranging from 38--44% \[[@pone.0152638.ref030], [@pone.0152638.ref031]\]. The mortality rate in our series is slightly lower (28.6%); all died from septic shock.

In this report, all the CRE were resistant to meropenem and ertapenem while 96% of them were resistant to imipenem. Variable resistance to carbapenems has been reported by other workers \[[@pone.0152638.ref019], [@pone.0152638.ref032]\]. This is attributed to alterations in porins leading to variable permeabilities to different carbapenems \[[@pone.0152638.ref033]\]. Although aztreonam is not inactivated by NDM-1 or other metallo-β-lactamase enzymes, approximately 91% of our CRE were resistant to aztreonam, which is essentially similar to the findings of other studies \[[@pone.0152638.ref024], [@pone.0152638.ref027]\] thus reflecting perhaps the presence of other resistance genes such as ESBLs or AmpC enzymes. Among the non-β-lactam antimicrobial agents, ciprofloxacin resistance was noted in 90.5% of the NDM-1 positive isolates. High-level resistance to amikacin and gentamicin was detected in 66.6% which may be related to the production of one or more of the 16S rRNA methyltransferases by some of the CRE isolates \[[@pone.0152638.ref034]\]. After exclusion of *Morganella* spp. and *Providentia* spp. which are intrinsically resistant to colistin, 90% of our isolates were susceptible to this drug, a finding already noted in other previous studies \[[@pone.0152638.ref024], [@pone.0152638.ref027]\]. However, after exclusion of *Morganella* spp. and *Providentia* spp. which are intrinsically resistant to tigecycline, only 52.6% of CRE were susceptible to tigecycline, a rate which is higher than those reported previously \[[@pone.0152638.ref024], [@pone.0152638.ref027]\].

There are multiple clones of NDM-1 producing *K*. *pneumoniae* and *E*. *coli* strains circulating in Kuwaiti hospitals. However, two *K*. *pneumoniae* and two *E*. *coli* isolates were clonally identical pointing to the potential of outbreaks due to some clones.

In conclusion, out study has established the prevalence of NDM-1 genes encoding carbapenem resistance amongst *Enterobacteriaceae* isolates in Kuwait and the high frequency of multi-drug resistance among these bacteria. Except for a small outbreak in one hospital, the majority of cases were sporadic. This report highlights the speed at which NDM-1-mediated resistance is spreading in the country which was not the case three years ago, when there was no case of CRE and MBL-positive isolates. This spread appears to be facilitated by different factors such as immigration, poor infection control practices, antibiotic misuse, and environmental spread.

Monitoring and control measures are important to prevent the spread of CRE. The Centers for Disease Control (CDC), Atlanta, GA, USA have published the guidelines for these \[[@pone.0152638.ref035]\]. The measures include: hand hygiene, contact precautions, healthcare personnel education, minimal use of invasive devices, laboratory reporting of CRE isolation to clinical and infection control staff, identification of CRE patients at admission, antibiotic stewardship, environmental cleaning, patient and staff cohorting, screening contacts of CRE patients, active surveillance testing and chlorhexidine bathing.
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